Ondine Biomedical Inc.

LSE OBI.L

Ondine Biomedical Inc. Capital Expenditure for the year ending December 31, 2023: USD -133.55 K

Ondine Biomedical Inc. Capital Expenditure is USD -133.55 K for the year ending December 31, 2023, a 41.79% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • Ondine Biomedical Inc. Capital Expenditure for the year ending December 31, 2022 was USD -229.42 K, a -276.87% change year over year.
  • Ondine Biomedical Inc. Capital Expenditure for the year ending December 31, 2021 was USD -60.88 K, a 21.65% change year over year.
  • Ondine Biomedical Inc. Capital Expenditure for the year ending December 31, 2020 was USD -77.70 K, a -206.00% change year over year.
  • Ondine Biomedical Inc. Capital Expenditure for the year ending December 31, 2019 was USD -25.39 K, a 74.14% change year over year.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
Loading...
SV Wall Street
LSE: OBI.L

Ondine Biomedical Inc.

CEO Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA
IPO Date Dec. 6, 2021
Location Canada
Headquarters 1100 Melville Street
Employees 18
Sector Healthcare
Industries
Description

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

Similar companies

AREC.L

Arecor Therapeutics plc

USD 0.68

-3.32%

POLB.L

Poolbeg Pharma PLC

USD 0.06

1.20%

StockViz Staff

February 6, 2025

Any question? Send us an email